Comparison Between Ultrasound Guided Ozone, Platelet-Rich Plasma or Steroid Injection in the Treatment of Sacroiliitis; a Randomized Double Blinded Controlled Study

Sponsor
Tanta University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05914350
Collaborator
(none)
105
1
3
21
5

Study Details

Study Description

Brief Summary

Comparison between ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis; a Randomized Double Blinded Controlled Study

Condition or Disease Intervention/Treatment Phase
  • Procedure: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
  • Drug: methylprednisolone acetate and lidocaine
  • Drug: PRP and lidocaine
  • Drug: medical ozone
N/A

Detailed Description

The sacroiliac joints (SIJ) are the largest axial joints in the human body. By aging, osteoarthritic degeneration occurs to SIJ. SIJ dysfunction typically results from abnormal motion and malalignment of the joint (1).

SIJ pain is one of the differential diagnoses of low back pain. Approximately, 10-25% of these patients will have SIJ dysfunction which should be considered clinically (1, 2). This pain affects physical, psychological and social aspects of the person reducing the work performance. It imposes a huge burden on nations globally (3, 4).

SIJ pain can be a difficult condition to treat and a multidisciplinary approach to treatment including multimodal medical, psychological, physical, and interventional approach is recommended (5).

Corticosteroids are a very magic therapy since their first use and they offer anti-inflammatory mechanisms to reduce low back pain and joint pain. SIJ steroid injections are typically performed for SIJ pain related to osteoarthritis, ligamentous sprain and sacroiliitis associated with inflammatory spondyloarthropathies (5, 6).

Intra-articular steroid injections have intermediate-term benefits, in which more than half of the patients had positive responses to treatment in a 6-month follow-up (7, 8).

Another treatment modality is Platelet-rich plasma (PRP) which is autologous blood that contains platelet concentrations above normal physiological levels (9). PRP is believed to stimulate regeneration through the release of growth factors and proteins that may be involved in repairing the degeneration (10, 11).

While corticostroid injection has rapid onset of pain releif with short duration, the PRP injection has delayed onset and long term of pain releif in recent studies (12-14).

Ozone therapy has been used in the treatment of many musculoskeletal diseases including low back pain (LBP), lumbar disk herniation, cervical pain, cervical disk herniation, failed back surgery syndrome, degenerative spinal disease, knee osteoarthritis, meniscal injuries, sacroiliitis, plantar fasciitis and carpal tunnel syndrome (8, 15). However, ozone therapy is not tested well in SIJ. Ozone has multiple mechanisms of action:, antioxidant, analgesic and antiinflammatory effects (16, 17).

Ultrasound has gained increasing popularity in pain management (18). Furthermore, it is a valuable tool for pain physicians in confirming the diagnosis of many musculoskeletal pain conditions (19). It has many advantages when compared to fluoroscopy techniques (20). It has no radiation exposure, procedures can be done outside operating room which will decrease the costs (21).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
105 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Comparison Between Ultrasound Guided Ozone, Platelet-Rich Plasma or Steroid Injection in the Treatment of Sacroiliitis; a Randomized Double Blinded Controlled Study
Anticipated Study Start Date :
Jun 23, 2023
Anticipated Primary Completion Date :
Mar 23, 2025
Anticipated Study Completion Date :
Mar 23, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group 1

40 mg methylprednisolone acetate and 1 mL lidocaine will be injected in sacroiliac joint in first week by ultrasound. While the second and third injections in the second and third weeks will be done by sham injection

Procedure: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis

Drug: methylprednisolone acetate and lidocaine
40 mg methylprednisolone acetate and 1 mL lidocaine

Experimental: Group 2

3 mL PRP and 1 mL lidocaine will be injected in sacroiliac joint by ultrasound once/week for 3 weeks

Procedure: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis

Drug: PRP and lidocaine
3 mL PRP and 1 mL lidocaine

Experimental: Group 3

10 ml of medical ozone of 20 μg/ml will be injected in sacroiliac joint by ultrasound once/week for 3 weeks

Procedure: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis

Drug: medical ozone
10 ml of medical ozone

Outcome Measures

Primary Outcome Measures

  1. Assessment of pain intensity using visual analog scale (VAS) [2 years]

    Primary outcome

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • One hundred and five patients, ASA physical status I - III, age 21 - 65 years, diagnosed with sacroiliitis.
Exclusion Criteria:
  • • Patient refusal

  • Psychological disturbance.

  • Local skin infection at the site of injection.

  • Ozone allergy

  • Coagulation disorders.

  • Chronic opioid use.

  • Sacroiliitis associated with disk pathology.

  • Severe ankylosing spondylitis.

  • History of corticosteroid injection within last three months.

  • Uncontrolled concomitant medical condition.

  • Severe arrhythmia, hypertensive crisis and other cardiovascular diseases.

  • Pregnant women.

  • Bowel inflammatory disease.

  • Psoriasis

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tanta University hospitals Tanta Egypt 31527

Sponsors and Collaborators

  • Tanta University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ahmed Abdelnaby Ibrahim, Ahmed elmaghrapy, Tanta University
ClinicalTrials.gov Identifier:
NCT05914350
Other Study ID Numbers:
  • 36264MD46/3/23
First Posted:
Jun 22, 2023
Last Update Posted:
Jun 22, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 22, 2023